Literature DB >> 23927436

Probing the effects of hapten stability on cocaine vaccine immunogenicity.

Xiaoqing Cai1, Timothy Whitfield, Amira Y Moreno, Yanabel Grant, Mark S Hixon, George F Koob, Kim D Janda.   

Abstract

Judicious hapten design has been shown to be of importance when trying to generate a viable vaccine against a drug of abuse. Hapten design has typically been predicated upon faithfully emulating the unique chemical architecture that each drug presents. However, the need for drug-hapten congruency may also compromise vaccine immunogenicity if the drug-hapten conjugate possesses chemical epitope instability. There has been no systematic study on the impact of hapten stability as it relates to vaccine immunogenicity. As a starting point, we have probed the stability of a series of cocaine haptens through varying several of its structural elements, including functionality at the C2-position, the nature of the linker, and its site of attachment. Accordingly, a hydrolytic stability profile of four cocaine haptens (GNNA, GNNS, GNE, and GNC) was produced, and these results were compared through each hapten's immunological properties, which were generated via active vaccination. From this group of four, three of the haptens, GNE, GNNA, and GNC, were further examined in an animal behavioral model, and findings here were again measured in relationship to hapten stability. We demonstrate a corresponding relationship between the half-life of the hapten and its immunogenicity, wherein haptens presenting a fully representative cocaine framework elicited higher concentrations of cocaine-specific IgG in sera and also conferred better protection against cocaine-induced locomotor activity. Our results indicate that hapten half-life plays an important role in vaccine immunogenicity and this in turn can impact animal behavioral effects when challenged with a drug of abuse.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23927436      PMCID: PMC3946501          DOI: 10.1021/mp400214w

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  20 in total

Review 1.  Vaccines targeting drugs of abuse: is the glass half-empty or half-full?

Authors:  Kim D Janda; Jennifer B Treweek
Journal:  Nat Rev Immunol       Date:  2011-12-16       Impact factor: 53.106

2.  Human therapeutic cocaine vaccine: safety and immunogenicity.

Authors:  Thomas R Kosten; Marc Rosen; Julian Bond; Michael Settles; John St Clair Roberts; John Shields; Lindsay Jack; Barbara Fox
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

3.  Cocaine vaccines: antibody protection against relapse in a rat model.

Authors:  M R Carrera; J A Ashley; B Zhou; P Wirsching; G F Koob; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

4.  Determination of affinity and specificity of anti-hapten antibodies by competitive radioimmunoassay.

Authors:  R Müller
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Psychomotor stimulant effects of cocaine in rats and 15 mouse strains.

Authors:  Morgane Thomsen; S Barak Caine
Journal:  Exp Clin Psychopharmacol       Date:  2011-10       Impact factor: 3.157

Review 6.  Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus.

Authors:  George Koob; Martin J Hicks; Sunmee Wee; Jonathan B Rosenberg; Bishnu P De; Stephen M Kaminsky; Amira Moreno; Kim D Janda; Ronald G Crystal
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-12       Impact factor: 4.388

Review 7.  Anti-cocaine vaccine development.

Authors:  Berma M Kinsey; Thomas R Kosten; Frank M Orson
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

8.  Covalent modification of proteins by cocaine.

Authors:  Shi-Xian Deng; Narine Bharat; Marian C Fischman; Donald W Landry
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

Review 9.  Cocaine pharmacology and current pharmacotherapies for its abuse.

Authors:  M Rocío A Carrera; Michael M Meijler; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2004-10-01       Impact factor: 3.641

10.  A second-generation vaccine protects against the psychoactive effects of cocaine.

Authors:  M R Carrera; J A Ashley; P Wirsching; G F Koob; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

View more
  15 in total

Review 1.  Recent advances in the molecular design of synthetic vaccines.

Authors:  Lyn H Jones
Journal:  Nat Chem       Date:  2015-12       Impact factor: 24.427

2.  Investigations into the efficacy of multi-component cocaine vaccines.

Authors:  Atsushi Kimishima; Margaret E Olson; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-12-20       Impact factor: 2.823

Review 3.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

Review 4.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

5.  Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination.

Authors:  Cody J Wenthur; Xiaoqing Cai; Beverly A Ellis; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-07-05       Impact factor: 2.823

6.  Cocaine Vaccine Development: Evaluation of Carrier and Adjuvant Combinations That Activate Multiple Toll-Like Receptors.

Authors:  Atsushi Kimishima; Cody J Wenthur; Lisa M Eubanks; Shun Sato; Kim D Janda
Journal:  Mol Pharm       Date:  2016-10-18       Impact factor: 4.939

7.  Hapten optimization for cocaine vaccine with improved cocaine recognition.

Authors:  Muthu Ramakrishnan; Berma M Kinsey; Rana A Singh; Thomas R Kosten; Frank M Orson
Journal:  Chem Biol Drug Des       Date:  2014-07-29       Impact factor: 2.817

8.  Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques.

Authors:  Suzette M Evans; Richard W Foltin; Martin J Hicks; Jonathan B Rosenberg; Bishnu P De; Kim D Janda; Stephen M Kaminsky; Ronald G Crystal
Journal:  Pharmacol Biochem Behav       Date:  2016-09-30       Impact factor: 3.533

9.  Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.

Authors:  J J Taylor; M Laudenbach; A M Tucker; M K Jenkins; M Pravetoni
Journal:  J Immunol Methods       Date:  2014-01-23       Impact factor: 2.303

Review 10.  The future potential for cocaine vaccines.

Authors:  Frank M Orson; Rongfu Wang; Stephen Brimijoin; Berma M Kinsey; Rana Ak Singh; Muthu Ramakrishnan; Helen Y Wang; Thomas R Kosten
Journal:  Expert Opin Biol Ther       Date:  2014-05-16       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.